VCM
CLRB icon

Vigilant Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Vigilant Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7
Closed -$6K – 446
2018
Q3 		$6K Buy
+7
New +$8.24K ﹤0.01% 412

Other funds holding CLRB

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Vigilant Capital Management's CLRB Position: Q4 2018 in Review

Vigilant Capital Management sold out of Cellectar Biosciences (CLRB) in Q4 2018, closing a stake of 7 shares — an estimated $6K sold.

Vigilant Capital Management first reported a position in CLRB in Q3 2018 and held it in 1 quarter. The position peaked at $6K in Q3 2018. 11 funds tracked by Wall St. Rank hold CLRB as of Q4 2018.

  • Vigilant Capital Management reported no remaining Cellectar Biosciences position as of Q4 2018 after selling out during the quarter.
  • Vigilant Capital Management sold 7 Cellectar Biosciences shares in Q4 2018, an estimated $6K.
  • Vigilant Capital Management first reported a position in Cellectar Biosciences in Q3 2018 and held it in 1 quarter.
  • Vigilant Capital Management's Cellectar Biosciences position peaked at $6K in Q3 2018.
  • 11 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2018.

Based on Vigilant Capital Management's 13F filing for Q4 2018, filed 15 Jan 2019.